Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1995-3-29
|
| pubmed:abstractText |
Several investigations have determined that the serum prostate specific antigen (PSA) concentration is dependent upon patient age and, as a result, reference ranges wider than 0.0 to 4.0 ng./ml. have been suggested for men 60 years old or older. To determine the clinical usefulness of the age-specific reference ranges--0.0 to 4.5 ng./ml. for men 60 to 69 years old and 0.0 to 6.5 ng./ml. for men 70 years old or older--the medical records of 2,988 men 60 years old or older who presented to a single urological practice were examined. All patients were evaluated with a serum PSA determination, digital rectal examination and transrectal ultrasound. A total of 1,686 prostate biopsies was performed (biopsy rate 56%) and 608 cancers were diagnosed (cancer detection rate 20%). By using the age-specific reference ranges as compared to the 0.0 to 4.0 ng./ml. reference range, the sensitivity of PSA for detecting early prostate cancer decreased by 9%, while the specificity and positive predictive value increased by 11% and 5%, respectively. If the age-specific reference ranges had been used 92 prostate biopsies (5.5%) performed could have been avoided, while 19 men in the study population (0.6%) would not have had prostate cancer diagnosed. Of the nondetected cancers 13 (67%) occurred in men 70 years old or older and 18 (95%) were small tumors of favorable pathological status unlikely to be of clinical consequence in these older men. These preliminary findings support the clinical usefulness of the wider age-specific reference ranges in men 60 years old or older. A prospective randomized clinical trial is currently underway to confirm the appropriateness of age-specific reference ranges compared to the reference range of 0.0 to 4.0 ng./ml.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0022-5347
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
153
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1160-3
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:7532725-Age Factors,
pubmed-meshheading:7532725-Aged,
pubmed-meshheading:7532725-Humans,
pubmed-meshheading:7532725-Male,
pubmed-meshheading:7532725-Middle Aged,
pubmed-meshheading:7532725-Predictive Value of Tests,
pubmed-meshheading:7532725-Prostate-Specific Antigen,
pubmed-meshheading:7532725-Prostatic Neoplasms,
pubmed-meshheading:7532725-Reference Values,
pubmed-meshheading:7532725-Sensitivity and Specificity
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
The use of age-specific reference ranges for serum prostate specific antigen in men 60 years old or older.
|
| pubmed:affiliation |
Department of Urology, Mayo Clinic, Rochester, Minnesota.
|
| pubmed:publicationType |
Journal Article
|